Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 149 for Ovarian

Edit search filters
  1. Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

    Rochester, MN

  2. A Study of Ovarian Tissue Freezing for the Preservation of Fertility in Children

    Rochester, MN

  3. Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (FRAPPE)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

    Rochester, MN

  5. Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

    Rochester, MN

  6. Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

    Scottsdale/Phoenix, AZ

  7. Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

    Rochester, MN

  8. Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Rochester, MN

  9. A Study of Adding AMG 479 to First Line Chemotherapy in Patients with Optimally Debulked Epithelial Ovarian Cancer

    Rochester, MN

  10. Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

    Rochester, MN

.

Mayo Clinic Footer